Loading...
Many patients have resistant hypertension, which is a failure to control blood pressure with available drugs and behavioral interventions. Hence, new treatment approaches are needed. The endothelin pathway is thought to contribute to hypertension, and currently no medications target this pathway. On the heels of positive preliminary evidence, investigators conducted an industry-supported, randomized, phase 3 trial of aprocitentan, a non–FDA-approved, once-daily, oral medication that blocks endothelin A and B receptors (NCT03541174). The primary endpoint was 4-week change in unattended office systolic blood pressure. Participants (≈700) had a systolic blood pressure above 140 mm Hg despite being on three antihypertensive drugs, including a d…